The latest update is out from Ascentage Pharma Group International ( (HK:6855) ).
Ascentage Pharma Group International announced a change in its company secretary and authorized representative roles, effective February 25, 2025. Mr. Wong Cheung Ki Johnny has resigned from these positions, and Ms. Chan Charmayne has been appointed as his successor. Ms. Chan brings over 17 years of experience in the company secretarial field and holds significant qualifications, positioning her well to support the company’s governance and compliance efforts. This transition is expected to maintain the company’s operational stability and adherence to regulatory requirements.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development of innovative therapies for cancer, hepatitis B, and age-related diseases. The company is listed on the Hong Kong Stock Exchange and is committed to advancing its pipeline of products to address unmet medical needs.
YTD Price Performance: -11.88%
Average Trading Volume: 3,048,627
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$13.83B
For an in-depth examination of 6855 stock, go to TipRanks’ Stock Analysis page.